Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD), a prospective, randomized, multi-center study to determine the efficacy of selected EEG and genotype biomarkers for predicting response to antidepressant therapy with escitalopram, bupropion XL, or a combination treatment regimen.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Bupropion (Primary) ; Escitalopram (Primary)
- Indications Depression; Major depressive disorder
- Focus Biomarker; Therapeutic Use
- Acronyms BRITE-MD
- 07 Mar 2012 Biomarkers information updated
- 06 Apr 2010 Actual patient number (375), additional lead trial centre added as reported by ClinicalTrials.gov.
- 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.